Goldman Sachs Group Inc Humanigen, Inc Transaction History

Goldman Sachs Group Inc

  • $605 Billion
  • Q3 2024

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

May 14, 2024
BUY
$1.76 - $3.33 $379,984 - $718,947
215,900 New
215,900 $382,000
Q2 2022

Aug 15, 2022
BUY
$1.76 - $3.33 $202,150 - $382,477
114,858 Added 113.67%
215,900 $382,000
Q1 2022

May 16, 2022
SELL
$1.81 - $3.97 $218,921 - $480,175
-120,951 Reduced 54.48%
101,042 $304,000
Q4 2021

Feb 14, 2022
BUY
$3.66 - $8.22 $615,524 - $1.38 Million
168,176 Added 312.5%
221,993 $826,000
Q3 2021

Nov 10, 2021
BUY
$5.93 - $17.83 $319,134 - $959,557
53,817 New
53,817 $319,000

Others Institutions Holding HGEN

# of Institutions
4
Shares Held
558K
Call Options Held
0
Put Options Held
0
View Full List

About HUMANIGEN, INC

HGEN Quotes by TradingView
  • Ticker HGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 103,661,000
  • Description
  • Humanigen, Inc., a clinical-stage biopharmaceutical company, focuses on preventing and treating an immune hyper-response called ?cytokine storm'. Lenzilumab is an antibody that binds to and neutralizes granulocyte-macrophage colony-stimulating factor (GM-CSF). The company is developing lenzilumab as a treatment for cytokine storm associated with...
More about HGEN
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email